Endotoxin “Priming” Potentiates Lung Vascular Abnormalities in Response to Escherichia coli Hemolysin: An Example of Synergism between Endo- and Exotoxin

By Dieter Walmrath, Hossein Ardeschir Ghofrani, Simone Rosseau, Hartwig Schütte, Antje Cramer, Werner Kaddus, Friedrich Grimminger, Sucharit Bhakdi,* and Werner Seeger

From the Department of Internal Medicine, Justus-Liebig University, 35385 Giessen, and the
*Institute of Medical Microbiology, Gutenberg-University, Mainz, 55101 Germany

Summary
The pore-forming hemolysin of Escherichia coli (HlyA), an important virulence factor in extraintestinal E. coli infections, causes thromboxane generation and related vasoconstriction in perfused rabbit lungs (Seeger, W., H. Walter, N. Suttorp, M. Muhly, and S. Bhakdi. 1989. J. Clin. Invest. 84:220). We investigated the influence of pulmonary vascular “priming” with endotoxin on the responsiveness of the lung to a low-dose HlyA challenge. Rabbit lungs were perfused with Krebs Henseleit buffer containing 0.1–100 ng/ml Salmonella abortus equi lipopolysaccharide (LPS) for 60–180 min. This treatment caused protracted release of tumor necrosis factor into the recirculating medium, but did not induce significant alterations of pulmonary hemodynamics and fluid balance. At a dose of 1 ng/ml, HlyA elicited only moderate thromboxane release (<200 pg/ml) and pulmonary artery pressure increase (~6 mmHg) in control lungs. Acceleration and potentiation of both the metabolic and vasoconstrictor response occurred in lungs primed with LPS. This priming effect displayed dose (threshold 0.1–1 ng/ml LPS) and time dependencies (threshold ~60–90 min LPS incubation). Maximum thromboxane release and pulmonary artery pressure increase surpassed the responses to HlyA in nonprimed lungs by more than 15-fold. Cyclooxygenase inhibition and thromboxane-receptor antagonism blocked these effects. These data demonstrate that LPS priming synergizes with HlyA challenge to provoke vascular abnormalities that are possibly relevant to the pathogenesis of organ failure in severe local and systemic infections.

Severe bacterial infection and sepsis are inevitably accompanied by the liberation of toxic microbial substances, of which LPS (endotoxin) is the most widely known (1). LPS may be released from a bacterial focus or circulating bacilli, or may be resorbed in enhanced quantities from the gastrointestinal tract under conditions of compromised mucosal barrier function (2, 3). Adverse effects evoked by LPS include micro-circulatory disturbances that lead to organ failure. These events appear to result from the activation of inflammatory cells and the production of secondary endogenous mediators rather than from direct cellular toxicity of LPS (1, 4, 5). In addition, low concentrations of LPS have been found to “prime” inflammatory cells in vitro for an enhanced responsiveness to a second inflammatory stimulus, e.g., lipid and peptide chemoattractants (6–15). In perfused lungs, enhanced reactivity to platelet activating factor was observed after pretreatment of the isolated organ with endotoxin (16).

In the present study, we investigated whether LPS priming might synergize with the action of a proteinaceous, pore-forming exotoxin to cause vascular abnormalities. We employed Escherichia coli hemolysin (HlyA)1 as a model toxin, since the pathogenetic relevance of this agent has been well established in animal models (17–19). An analogous role as virulence factor in human infections has been inferred from the high association of HlyA production with disease, including pyelonephritis and septicemia (18, 20, 21). HlyA exerts a particularly potent action on neutrophils, monocytes, and endothelial cells, where secondary cellular events such as generation of inflammatory mediators may be mediated not only by passive calcium flux through toxin pores, but also via trig-

1 Abbreviation used in this paper: HlyA, hemolysin.
gering of the preformed phosphatidylinositol hydrolysis-related signal transduction pathway (22-27). In human neutrophils, the toxin thus evokes degranulation, production of reactive oxygen species, and lipid mediator synthesis (23-25, 28). Interest in HlyA has been boosted by the recognition that this toxin represents the prototype of a large family of structurally and functionally related pore-forming toxins produced by other gram-negative bacteria (29-34).

To address possible cooperative effects of LPS priming and HlyA efficacy, we have employed the model of the buffer-perfused rabbit lung. This provides a means to investigate the pathogenesis of inflammatory organ injury in the absence of plasma proteins and circulating blood cells. Infusion of viable HlyA-producing E. coli, but not of genetically related toxin-negative strains, was previously found to provoke pulmonary hypertension and pulmonary edema in the perfused lungs (35). Similar effects were discerned when low doses of purified HlyA were applied (36). Here, we demonstrate a remarkable synergism between LPS and HlyA. Preexposure of the perfused rabbit lungs to the LPS primed the organs for markedly accelerated and enhanced responsiveness to low-dose HlyA challenge. Such synergism between endotoxin and a membrane-damaging exotoxin may be widely operative and relevant to the pathogenesis of vascular abnormalities in severe infection and sepsis.

Materials and Methods

Reagents. Goat anti-human TNF-α with established cross-reactivity with rabbit TNF-α was graciously provided by J. C. Mathison (Scripps Research Institute, La Jolla, CA), and Salmonella abortus equi endotoxin by C. Galanos (Max Planck Institute of Immunology, Freiburg, Germany). d,l-Lysin-mono-acetylsalicylate/glycine (9:1; ASA) was obtained from Bayer AG (Leverkusen, Germany), BM 13.505 from Boehringer AG (Mannheim, Germany), and MTT from Sigma (Munich, Germany). Rabbit anti-TxB 2 was from Pässel AG (Frankfurt, Germany), and recombinant murine TNF-α from Genzyme (Frankfurt, Germany). Tritium-labeled TxB 2 was purchased from New England Nuclear (Dreieich, Germany). A photometric test for the detection of LPS was obtained from Kabi Vitrum (Coatest endotoxin; Munich, Germany). All other biochemicals were obtained from Merck AG (Darmstadt, Germany).

Preparation of HlyA. HlyA was purified as previously described (37). The toxin was recovered in active and monomeric form, and the LPS contamination of the preparation used was <3 ng/µg protein.

Perfused Rabbit Lungs. The model has been previously described in detail (38-40). The lungs were perfused with Krebs Henseleit buffer through cannula in the pulmonary artery and the left atrium (flow 100 ml/min; left atrial pressure 2 mm Hg), being placed in a temperature-equilibrated housing chamber at 37°C and freely suspended from a force transducer. They were ventilated with room air supplemented with 4% CO 2 (tidal volume 8-14 ml/kg, frequency 25-30 breaths/min; positive endexpiratory pressure of 1.5 mmHg). The alternate use of two separate perfusion circuits, each containing 250 ml, allowed exchange of perfusion fluid. Perfusion pressure, ventilation pressure, and the weight of the isolated organ were registered continuously. Lungs selected for the study were those that (a) had a homogenous white appearance without signs of hemostasis or edema formation; (b) had pulmonary artery and ventilation pressures in the normal range; and (c) were isogravimetric (lung weight gain <0.3 g/h) during an initial steady state period of at least 45 min.

Biochemical Measurements. TxB 2 was assayed by RIA as described (19). TNF-α was determined in a cytolytic cell assay in the mouse fibrosarcoma cell line WEHI 164 clone 13 (kindly donated by Dr. T. Espevik, University of Trondheim, Trondheim, Norway), as previously described (41). The WEHI cells (2 × 10 6) were incubated with serial dilutions of perfusate in microtiter wells (Nunc, Rothesild, Denmark). After 18 h, MTT (5 mg/ml in PBS; 100 µl/well) was added. The reaction was stopped after 4 h by addition of 5% formic acid in 2-propanol, and the content of reduced MTT was read in a microELISA autoreader (570 nm). The titer of TNF-α is expressed in U/ml and was chosen as the reciprocal of the dilution necessary to cause 50% cytotoxicity. Recombinant murine TNF-α served as standard in all assays. The sensitivity of WEHI 164.13 ranged between 0.8 and 0.02 pg protein/cytolytic unit in the different experiments. Rabbit TNF-α units were expressed as picograms of murine recombinant TNF-α protein to compensate for the variance in sensitivity. To establish the nature of the cytolytic activity as TNF-α, an antisera directed against human TNF-α with established cross-reactivity with rabbit TNF-α (42) was added to the perfusates. It was found that it neutralized all cytolytic activity measured with the WEHI cells. Potassium was measured according to standard techniques.

Experimental Protocol. After a steady-state period of 40 min, the recirculating perfusate was exchanged with fresh buffer medium, and time was set at zero. Different quantities of LPS in 500 µl PBS or the vehicle only were admixed to the buffer fluid and recirculated for 60-180 min. Thereafter, HlyA, dissolved in 250 µl saline, was bolus injected into the pulmonary artery to achieve a final buffer concentration of 1 ng/ml, and recirculation was continued for another 20 min. 1 ml-perfusate samples for determination of TxB 2 and potassium and 3-ml samples for TNF measurements were taken every hour during the period of LPS or sham priming and 2, 5, 10, and 20 min (TxB 2, K +) as well as 20 min (TNF) after application of HlyA.

Results

Pressor Responses. Under baseline conditions, the pulmonary artery pressure ranged between 5 and 10 mmHg in all experiments. Admixture of 0.1 and 1 ng/ml LPS to the buffer fluid did not exert any effect on the baseline vascular pressure (Fig. 1; Table 1). 10 and 100 ng/ml LPS provoked only minor increases in pressure values that never exceeded 4 mmHg.

In nonprimed lungs, bolus injection of 1 ng/ml HlyA caused a slight, protracted rise in pulmonary artery pressure, with maximum increases between 5 and 6 mmHg within 20 min. These pressor responses were potentiated in a time- and dose-dependent manner by priming with LPS. Taking 120 min as standard priming time, pressure increments up to >70 mmHg were provoked upon subsequent HlyA challenge (Figs. 1 and 2), and the vasocostrictor response occurred much more rapidly: more than two thirds of the maximum pressure rise was complete within 1 min in lungs primed with 1 and 10 ng/ml LPS, whereas the maximum pressure elevation evoked by HlyA application in nonprimed lungs occurred after approximately 20 min.

Fig. 3 shows the time dependency of the LPS priming process, using 10 ng/ml LPS. No augmentation of the vasocon-
A minimal priming period of 60 min was required to provoke a moderate amplification of the pressor response, and a steep increase in priming efficacy occurred in the 60–120 min post-LPS period. Maximum responses, although showing off-leveling of the dose-dependency curve, were observed in lungs preexposed to LPS for 180 min.

Thromboxane Generation. Only minor liberation of TxB₂ was noted in control lungs and in lungs undergoing the LPS priming procedure up to 3 h (Table 2). Application of 1 ng/ml HlyA alone provoked only moderate thromboxane release (<200 pg/ml). In LPS-primed organs, however, marked liberation of the prostanoid occurred in response to subsequent challenge with the exotoxin, whereby similar strict dependency on the priming time was noted. More than 30-fold increases in circulating TxB₂ levels were provoked within 20 min to HlyA challenge in lungs preincubated with 10 ng/ml LPS for 2 h. After 3-h priming, a greater than 10-fold increase in exotoxin-elicited TxB₂ levels occurred within only 2 min.

TNF Liberation. Lungs perfused with the buffer alone released only very small amounts of TNF into the recirculating fluid. Infusion of LPS resulted in a progressive release of this
Figure 3. Time dependency of LPS priming with respect to vasoconstrictor responses provoked by HlyA. Lungs were perfused with 10 ng/ml LPS for various time periods, followed by injection of HlyA (final concentration, 1 ng/ml) into pulmonary artery. Maximum rises in pulmonary artery pressure (delta PAP) measured within 20 min after exotoxin application are given in mean ± SEM (n = 4 experiments each).

Effect of Thromboxane Inhibition on Pressor Responses. Lungs were primed with 10 ng/ml LPS for 180 min. Acetylsaliclic acid (250 μM) or BM 13.505 (10 μM; 43) was then admixed to the buffer fluid 5 min before HlyA challenge (1 ng/ml; n = 4 experiments each). Rises in pulmonary artery pressure were then found to be restricted to 8.5 ± 2.5 and 6.3 ± 1.8 mmHg, respectively, as compared with 64 ± 12 mmHg in the absence of either inhibitor.

Lung Edema Formation and Potassium Liberation. Total weight gain of the isolated organs ranged below 2 g over the entire LPS priming procedure at all endotoxin doses used (Table 1). The dramatic vasoconstrictor responses elicited by HlyA in LPS-primed organs resulted in rapid edema formation at pulmonary artery pressure levels >30 mmHg. In lungs with maximum LPS priming (3-h preincubation with 10 and 100 ng/ml LPS), the exotoxin-elicited weight gain exceeded 15 g, and experiments were terminated at this level of edema formation.

LPS priming did not result in any significant liberation of potassium into the recirculating buffer medium. Intravascular application of 1 ng/ml HlyA provoked significant potas-

Table 2. Thromboxane B2 Generation in Response to LPS Priming and HlyA Stimulation

| Priming Time | LPS-dose | HlyA-dose | Pre-priming | Post-priming | 2' | 5 | 10' | 20' |
|--------------|----------|-----------|-------------|--------------|----|---|-----|-----|
| min          | ng/ml    | ng/ml     |             |              |    |   |     |     |
| 180          | 0        | 0         | 87.0 ± 16   | 99.5 ± 11    | 103 ± 11 | 100.3 ± 15 | 91.3 ± 6 | 79.0 ± 17 |
| 180          | 10       | 0         | 73.3 ± 15   | 116.5 ± 18   | 12.3 ± 15 | 12.3 ± 16 |
| 180          | 0        | 1         | 72.2 ± 7    | 70.2 ± 8     | 99.4 ± 11 | 123.8 ± 15 | 198.0 ± 16 | 181.2 ± 16 |
| 0            | 10       | 1         | 68.0 ± 21   | 69.4 ± 12    | 69.9 ± 15 | 69.0 ± 16 | 70.5 ± 19 |
| 60           | 10       | 1         | 66.0 ± 16   | 64.5 ± 12    | 81.0 ± 15 | 105.7 ± 15 | 120.7 ± 19 | 162.7 ± 19 |
| 90           | 10       | 1         | 62.0 ± 12   | 75.0 ± 12    | 136.0 ± 15 | 184.0 ± 15 | 246.0 ± 15 | 823.0 ± 15 |
| 120          | 10       | 1         | 58.0 ± 11   | 78.0 ± 12    | 572.0 ± 15 | 605.0 ± 15 | 985.0 ± 15 | 3133.0 ± 15 |
| 180          | 10       | 1         | 74.0 ± 8    | 101.0 ± 14   | 1191.0 ± 15 | 1279.0 ± 15 | 1937.0 ± 15 | 3903.0 ± 15 |

* In lungs with high dose LPS priming for 3 h, HlyA stimulation provoked marked edema formation. These experiments were terminated in advance, when total lung weight gain surpassed 15 g.
Figure 4. Liberation of TNF into the lung perfusate during LPS priming. Lungs were perfused with various LPS concentrations for 3 h. TNF concentrations in the recirculating buffer fluid are given (mean ± SEM; n = 4 experiments each).

sium release within 20 min (0.32 ± 0.04 mmol). These values were independent of LPS priming (data not shown).

Discussion

Parenteral application of LPS reproduces pathophysiologic sequelae of sepsis and ARDS in many animal models (44). The endotoxin responsiveness of the pulmonary vasculature in terms of vasoconstriction and vascular leakage is, however, species dependent. In the present investigation, no or only very minor changes in pulmonary artery pressure and lung fluid balance were observed within 3-h exposure of rabbit lungs to LPS at concentrations of 0.01-100 ng/ml. This low responsiveness is in accord with data obtained in previous studies in buffer-perfused goat (45) and rat lungs (46). It may be due to several factors, including the absence of plasma-borne endotoxin binders such as the LPS-binding protein LBP (3, 47), and the lack of endotoxin-sensitive humoral mediator systems such as the complement cascade. Nevertheless, LPS did provoke significant cytokine generation. Kinetics of TNF appearance (<120 min) and maximum perfusate concentrations of this cytokine (range up to 500 pg/ml; i.e., 5,000 U/ml) corresponded roughly to data reported for intact rabbits with intravascular endotoxin application (peak TNF concentrations ~2,500 U/ml plasma within 45-100 min; [42]). Lung macrophages are a likely source for TNF (48). It is noteworthy that TNF alone provoked no severe vascular abnormalities and organ injury in our experiments.

When given as sole stimulus, HlyA applied at the very low dose of 1 ng/ml provoked only marginal TxB2 release and a corresponding moderate increase in pulmonary artery pressure (36). However, dramatically altered responses were observed in lungs primed with LPS, where amplification and acceleration of prostanoid release and pulmonary artery pressure elevation were registered. The potent vasoconstrictor agent thromboxane apparently represented the predominant mediator of the pressor response. Finally this was largely suppressed by cyclooxygenase inhibition and TxA2-receptor antagonism. The cellular source of thromboxane in our model is not established, however, lung macrophages represent likely candidates. Preincubation of macrophages with LPS in vitro primes these cells for accelerated and enhanced arachidonate metabolite release in response to subsequent stimulation with opsonized zymosan and the calcium-ionophore A23187, with a half-maximal priming time of ~20 min, and a maximal effect after 50-60 min (6, 11, 49). These features correspond approximately to the characteristics of priming time (obvious effects after ~60 min) and efficacy (acceleration and enhancement of response) in the present study. Further to this, intravascularly sequestered neutrophils, residing in the capillary bed despite extensive buffer-perfusion of the isolated organs (50), may also be targets for synergism between LPS and HlyA. These cells are known to be responsive to both HlyA stimulation (24, 25) and LPS priming (8-10, 15), and neutrophil-derived mediators such as oxygen radicals are potent inductors of lung thromboxane generation (43, 51, 52).

The precise cellular mechanisms of LPS priming are unknown, and many possibilities are under discussion (15, 53, 54). In addition, secondary induction of TNF might add to the priming efficacy of LPS, as suggested from in vitro studies (15, 53, 55). These unresolved questions notwithstanding, it is important to realize that LPS priming can precipitate rapid and total collapse of the lung vascular homeostasis upon challenge with a common membrane-damaging toxin. Pore formers are produced by many other pathogenic microorganisms (31, 32, 56, 57), and their synergism with LPS or other priming agents could be relevant to the pathogenesis and manifestation of organ lesions during severe infections.

The authors thank E. Becker for excellent technical assistance and Dr. R. L. Snipes for thorough linguistic editing of the manuscript.

This work was supported by the Deutsche Forschungsgemeinschaft (Klinische Forschergruppe "Respiratorische Insuffizienz"; SFB 311).

Address correspondence to Prof. Werner Seeger, Department of Internal Medicine, Justus-Liebig University Giessen, Klinikstrasse 36, 35392 Giessen, Germany.

Received for publication 5 April 1994 and in revised from 24 June 1994.
References

1. Olson, N.C., W.L. Salzer, and C.E. McCall. 1988. Biochemical, physiological, and clinical aspects of endotoxemia. Mol. Aspects Med. 1:511.

2. Brigham, K.L., and B. Meyrick. 1986. Endotoxin and lung injury. Am. Rev. Respir. Dis. 133:913.

3. Raetz, C.R.H., R.J. Ulevitch, S.D. Wright, C.H. Sibley, A. Ding, and C.F. Nathan. 1991. Gram-negative endotoxin: An extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB (Fed. Am. Soc. Exp. Biol.). 5:2652.

4. Sutherland, I.W. 1985. Biosynthesis and composition of gram-negative bacterial extracellular and wall polysaccharides. Annu. Rev. Microbiol. 39:243.

5. Rietschel, E., Th. 1984. Handbook of endotoxin, volume 1. In Chemistry of Endotoxin. Elsevier Science Publishing Co., New York. 411 pp.

6. S. Aderem, A.A., D.S. Cohen, S.D. Wright, and Z.A. Cohn. 1986. Bacterial lipopolysaccharides prime macrophages for enhanced release of arachidonic acid metabolites. J. Exp. Med. 164:165.

7. Christiansen, J.W., S.F. Petras, P.M. Vacek, and G.S. Davis. 1989. Rat alveolar macrophage production of chemotactants for neutrophils: response to Escherichia coli endotoxin. Infect. Immun. 57:810.

8. Doerfler, M.E., R.L. Danner, J.H. Shelhamer, and J.E. Parillo. 1986. Bacterial lipopolysaccharides prime human neutrophils for enhanced production of leukotriene B4. J. Clin. Invest. 83:970.

9. Forehand, J.R., M.J. Pabst, W.A. Phillips, and R.B. Johnston, Jr. 1989. Lipopolysaccharide priming of human neutrophils for an enhanced respiratory burst. J. Clin. Invest. 83:74.

10. Goldman, D.W., H. Enkel, L.A. Gifford, D.E. Chenoweth, and J.T. Rosenbaum. 1986. Lipopolysaccharide modulates receptors for leukotriene B4, C5a, and Formyl-Methionyl-Leucyl-Phenylalanine on rabbit polymorphonuclear leukocytes. J. Immunol. 137:1971.

11. Pabst, M.J., and R.B. Johnston, Jr. 1980. Increased production of superoxide anion by macrophages exposed in vitro to muramyl dipeptide or lipopolysaccharide. J. Exp. Med. 151:101.

12. Prpic, V., J.E. Weil, S.D. Somers, J. DiGuiseppi, S.P. Goniak, S.V. Pizzo, T.A. Hamilton, B. Herman, and D.O. Asams. 1987. Effects of bacterial lipopolysaccharide on the hydrolysis of phosphatidylinositol-4,5-biphosphate in murine peritoneal macrophages. J. Immunol. 139:52.

13. Suttorp, N., Ch. Galanos, and N. Neuhofer. 1987. Endotoxin alters arachidonate metabolism in pulmonary endothelial cells. Am. J. Physiol. 253:C384.

14. Szefler, S.J., C.E. Norton, B. Ball, J.M. Gross, Y. Aida, and M.J. Pabst. 1989. IFN and LPS overcome glucocorticoid inhibition of priming for superoxide release on human monocytes. J. Immunol. 142:3985.

15. Thelen, M., A. Rosen, A.C. Nairn, and A. Aderem. 1990. Tumor necrosis factor alpha modifies agonist-dependent responses in human neutrophils by inducing the synthesis and myristoylation of a specific protein kinase C substrate. Proc. Natl. Acad. Sci. USA. 87:5603.

16. Salzer, W.L., and C.E. McCall. 1990. Primed stimulation of isolated perfused rabbit lung by endotoxin and platelet activating factor induces enhanced production of thromboxane and lung injury. J. Clin. Invest. 85:1135.

17. Cavalieri, S.J., G.A. Behach, and I.S. Snyder. 1984. Escherichia coli alpha-hemolysin: characteristics and probable role in pathogenicity. Microbiol. Rev. 48:326.

18. Welch, R.A., E.P. Dellinger, B. Minshew, and S. Palkow. 1981. Pore-forming E. coli hemolysin contributes to virulence of extra-intestinal E. coli infections. Nature (Lond.). 294:665.

19. Hacker, J., C. Hughes, H. Hof, and W. Goebel. 1983. Closed hemolysin genes from Escherichia coli that cause urinary tract infection determine different levels of toxicity in mice. Infect. Immun. 42:57.

20. Füntfrücht, R., H. Tschöpe, G. Stein, H. Kunath, M. Bergner, and G. Wessel. 1986. Virulence properties of Escherichia coli strains in patients with chronic pyelonephritis. Infection. 14:145.

21. Welch, R.A., and S. Palkow. 1984. Characterization of Escherichia coli hemolysins conferring quantitative differences in virulence. Infect. Immun. 43:156.

22. Bhakdi, S., S. Greulich, M. Muhly, S. Korom, and G. Schmidt. 1990. Effects of E. coli hemolysin on human monocytes: cytochemical action and stimulation of interleukin-1 release. J. Clin. Invest. 85:1746.

23. Bhakdi, S., M. Muhly, U. Mannhardt, F. Hugo, K. Klapek, C. Mueller-Eckhardt, and L. Roka. 1988. Staphylococcal alpha toxin promotes blood coagulation via attack on human platelets. J. Exp. Med. 168:52.

24. Grimminger, F., C. Scholz, S. Bhakdi, and W. Seeger. 1991. Subhemolytic doses of Escherichia coli hemolysin evoke large quantities of lipoxygenase products in human neutrophils. J. Biol. Chem. 266:14262.

25. Grimminger, F., U. Sibelius, S. Bhakdi, N. Suttorp, and W. Seeger. 1991. Escherichia coli hemolysin is a potent inductor of phosphoinositide hydrolysis and related metabolic responses in human neutrophils. J. Clin. Invest. 88:1531.

26. Suttorp, N., B. Füntfrücht, W. Seeger, H. Schmitt, and S. Bhakdi. 1990. Effects of E. coli hemolysin on endothelial cell function. Infect. Immun. 58:3796.

27. Suttorp, N., M. Fuhrmann, S. Tannert-Otto, F. Grimminger, and S. Bhakdi. 1993. Pore-forming bacterial toxins potently induce release of nitric oxide in porcine endothelial cells. J. Exp. Med. 178:337.

28. Bhakdi, S., and E. Martin. 1991. Superoxide generation by human neutrophils induced by low doses of Escherichia coli hemolysin. Infect. Immun. 59:2955.

29. Eberspächer, B., F. Hugo, M. Pohl, and S. Bhakdi. 1990. Functional similarity between the haemolysins of Escherichia coli and Morganella morganii. J. Med. Microbiol. 33:165.

30. Ikawa, M., E.T. Lally, P. Berthold, H.M. Korck, and N.S. Tächich. 1980. Effects of cations and osmotic protectants on cytolytic activity of Actinobacillus actinomycetemcomitans leukotoxin. Infect. Immun. 58:1782.

31. Lof, R.Y., C.A. Strathdee, and P.E. Shewen. 1987. Nucleotide sequence of the leukotoxin genes of pasteurella haemolytica A1. Infect. Immun. 55:1987.

32. Braun, V., and T. Focaretta. 1991. Pore-forming bacterial protein hemolysins (cytolysins). Crit. Rev. Microbiol. 18:115.

33. Strathdee, C.A., and R.Y. Lo. 1987. Extensive homology between the leukotoxin of Pasteurella haemolytica A1 and the alpha hemolysin of Escherichia coli. Infect. Immun. 55:3233.

34. Welch, R.A. 1991. Pore-forming cytolysins of gram-negative bacteria. Mol. Microbiol. 5:321.

35. Seeger, W., R. Obersnitz, M. Thomas, D. Walmrath, J.B. Holland, F. Grimminger, B. Eberspächer, F. Hugo, N. Suttorp, and S. Bhakdi. 1991. Lung vascular injury after administration of viable hemolysin-forming Escherichia coli in isolated rabbit lungs. Am. Rev. Respir. Dis. 143:797.

36. Seeger, W., H. Walter, N. Suttorp, M. Muhly, and S. Bhakdi.
1989. Thromboxane-mediated hypertension and vascular leakage evoked by low doses of Escherichia coli hemolysin in rabbit lungs. *J. Clin. Invest.* 84:220.

37. Bhakdi, S., N. Mackman, J.M. Nicaud, and I.B. Holland. 1986. Escherichia coli hemolysin may damage target cell membranes by generating transmembrane pores. *Infect. Immun.* 52:63.

38. Seeger, W., D. Walmrath, M. Menger, and H. Neuhof. 1986. Increased lung vascular permeability after arachidonic acid and hydrostatic challenge. *J. Appl. Physiol.* 61:1781.

39. Grimminger, F., G. Becker, and W. Seeger. 1988. High yield enzymatic conversion of intravascular leukotriene A₄ in blood-free perfused lungs. *J. Immunol.* 141:2431.

40. Seeger, W., D. Walmrath, and F. Grimminger. Acute respiratory distress syndrome—model systems using the isolated perfused rabbit lung. 1994. In *Oxygen Radicals in Biological Systems*, Part C. L. Packer, editor. (A volume of Methods Enzymol. J.N. Abelson and M.I. Simon, editors). Academic Press, Inc. Orlando. 233:549.

41. Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line. WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. *J. Immunol. Methods.* 95:99.

42. Mathison, J.C., E. Wolfson, and R.J. Ulevitch. 1988. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. *J. Clin. Invest.* 81:1925.

43. Seeger, W., C. Ernst, D. Walmrath, H. Neuhof, and L. Roka. 1985. Influence of the thromboxane antagonist BM 13.177 on the arachidonic acid-induced increase in pulmonary vascular resistance and permeability in rabbit lungs. *Thromb Res.* 40:793.

44. Brigham, K.L., and R Meyrick. 1986. Endotoxin and lung injury. *Am. Rev. Respir. Dis.* 133:913.

45. Winn, R., S. Nickelson, and C.L. Rice. 1988. Fluid filtration coefficient of isolated goat lungs of lipopolysaccharide (LPS) and LPS binding protein. *J. Appl. Physiol.* 64:2463.

46. Feuerstein, N., and P.W. Ramwell. 1981. In vivo and in vitro effects on prostaglandin release from rat lung. *Br. J. Pharmacol.* 73:511.

47. Wright, S.D., R.A. Ramos, P.S. Tobias, R.J. Ulevich, and J.C. Mathison. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. *Science (Wash. DC).* 249:1431.

48. Kelley, J. 1990. Cytokines of the lung. *Am. Rev. Respir. Dis.* 141:765.

49. Aderem, A.A., and Z.A. Cohn. 1988. Calcium ionophore synergizes with bacterial lipopolysaccharides in activating macrophage arachidonic acid metabolism. *J. Exp. Med.* 167:623.

50. Ernert, L., W. Seeger, and H.R. Duncker. 1993. Computer-assisted morphometry of the intracapillary leukocyte pool in the rabbit lung. *Cell Tissue Res.* 271:469.

51. Seeger, W., N. Suttorp, F. Schmidt, and H. Neuhof. 1986. The glutathione redox cycle as a defense system against prostanoïd formation and vasoconstriction in rabbit lungs. *Am. Rev. Respir. Dis.* 133:1029.

52. Repine, J.E., R.B. Fox, E.M. Berger, A. Vatter, D.M. Shasby, C.M. Bowman, and R.N. Harada. 1981. Potential mechanisms of lung injury from hydroxyl radical. *Chest.* 80:45.

53. Magnusson, D.K., R.V. Maier, and T.H. Pohlmann. 1988. Protein kinase C: A potential pathway of endothelial cell activation by endotoxin, tumor necrosis factor, and interleukin-1. *Surgery.* 106:216.

54. Romano, M., and J. Hawiger. 1990. Interaction of endotoxin lipid A and lipid X with purified human platelet protein kinase C. *J. Biol. Chem.* 265:1765.

55. Dinarello, C.A. 1991. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. *Curr. Opin. Immunol.* 3:941.

56. Bhakdi, S., and J. Tranum Jensen. 1988. Damage to cell membranes by pore-forming bacterial cytolysins. *Prog. Allergy.* 40:1.

57. Bhakdi, S., U. Weller, I. Walev, E. Martin, D. Jonas, and M. Palmer. 1993. A guide to the use of pore-forming toxins for controlled permeabilization of cell membranes. *Med. Microbiol. Immunol.* 182:167.